4α-Methylcholesterol is a Cholesterol derivative. 4α-Methylcholesterol can oxidize 3-hydroxy steroid, with the apparent Km of 12.6 μM.

A small molecule that disrupt 14-3-3 dimers at low micromolar concentrations and induce rapid down-regulation of Raf-MAPK and PI3K-Akt signaling in Jurkat cells.

5α-Cholesta-7,24-dien-3β-ol, a sterol, can be found in hamster cauda epididymal mature spermatozoa.

Desmosterol is an endogenous agonist of RORgamma; Intermediate in the synthesis of cholesterol.

Lathosterol is a cholesterol-like molecule. Serum Lathosterol concentration is an indicator of whole-body cholesterol synthesis.

Cholestenone is the intermediate oxidation product of cholesterol.

CDM-NAG is a useful tool compound to deliver the siRNA.

JSD26 is a selective S-nitroso-coenzyme A reductase 2 (SCoR2; AKR1A1) inhibitor with Ki of 93 nM, 10-fold selectivity over AKR1B1.

VV261 is an orally active Influenza Virus inhibitor. VV261 has demonstrated activity against severe febrile thrombocytopenia syndrome virus (SFTSV) and lymphocytic choriomeningitis virus (LCMV) (EC50: 0.89 and 0.15, respectively).

Antabactin (ANT) is a highly potent pan-abscisic acid (ABA) receptor antagonist with EC50 of 760 nM and picomolar dissociation constant, disrupts signaling by preventing receptor-PP2C interactions.

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM, respectively.

Zelavespib (PU-H71) is a potent Hsp90 inhibitor, with an IC50 of 51 nM in MDA-MB-468 cells.

PAR2 antagonist C391 (C391) is a selective PAR2 antagonist, potently inhibits peptidomimetic-induced PAR2 Ca2+ signalling with IC50 of 1.3 uM.C391 blocks both PAR2 Ca2+ and MAPK signalling pathways activated by peptidomimetics and/or proteinase activation.C391 effectively attenuated compound 48/80-induced thermal hyperalgesia in vivo.C391 blocked A. alternata-induced, PAR2-dependent Ca2+ and MAPK signalling in 16HBE14o- cells, as well as β-arrestin recruitment in HEK 293 cells.C391 effectively attenuated A. alternata-induced inflammation, mucus production, mucus cell hyperplasia and airway hyperresponsiveness in acute allergen-challenged murine models.

DS03090629 is a potent, selective, ATP-competitive and orally available MEK1/2 inhibitor, shows high affinity for the MEK protein regardless of its phosphorylation status (npMEK (inactive) Kd=0.11 nM, and pMEK (active) Kd=0.15 nM).

Dizocilpine maleate(MK 801) is a potent N-methyl-D-aspartate (NMDA) receptor antagonist with Ki of 30.5 nM

CFTR Inhibitor II is a cell-permeable glycinyl hydrazone compound that acts as a potent, selective and reversible open-channel blocker of CFTR with intermediate speed (< 1 min; 95% inhibition at 50 µM; Ki = 4.3 µM in CFTR-expressing FRT cells.

Procyanidin B2 is a natural flavonoid, with anti-cancer, antioxidant activities.

DDAO is a promising near-infrared (NIR) red fluorescent probe with tunable excitation wavelength (600-650 nm) and long emission wavelength (λem = 656 nm). DDAO can de desiged for detection of the activities of different enzymes such as β-galactosidase, sulfatase, protein phosphatase 2A, carboxylesterase 2, human albumin and esterases.

Hs-27 is a Novel Hsp90 Inhibitor, Exhibits Diagnostic and Therapeutic Potential in Triple Negative Breast Cancer.

A novel Non-competitive AMPA/kainate antagonist.

JNJ-7777120 is a selective H4R antagonist with Ki of 4 ±1 nM, exhibits >1000-fold selectivity over the other histamin receptors.

A novel Non-competitive AMPA/kainate antagonist.

LY294002 is a PI3K inhibitor for p110α, p110δ and p110β with IC50 of 0.5 μM, 0.57 μM and 0.97 μM, respectively.

Selective cell permeable phosphatidylinositol 3-kinase (PI3K) inhibitor

iCRT 14 is a novel potent inhibitor of β-catenin-responsive transcription (CRT) (IC50 = 40.3 nM in assays of Wnt pathway activity).

Benzamil hydrochloride is a specific and potent sodium channel (ENaC) blocker.

MG-132 is an inhibitor of proteasome with IC50 of 100 nM, and also inhibits calpain with IC50 of 1.2 μM.

H2DCFDA is a fluorescent cell permeabl ROS indicator.

CLR1501 is a synthetic analogs of the tumor-targeting agent alkylphosphocholine (APC), which is specifically attracted to cancer cells.

CMP8 is a high-affinity ligand that binds only to mutant ERLBD.